Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Post by Busyzzindahouseon Jan 04, 2018 8:56pm
142 Views
Post# 27285960

lvl 2 at close

lvl 2 at closequite a few lined up to buy towards the end of the day..... rest assured quite a few new hands availed of the KALY sale today. Wish i had more

Level 2 Quote

Level two quotes - Bid
Number of Shares Bid Price
 
10,000 shares
10,000 0.445
 
136,500 shares
136,500 0.440
 
74,000 shares
74,000 0.435
 
156,500 shares
156,500 0.430
 
15,500 shares
15,500 0.425
 
119,500 shares
119,500 0.420
 
22,000 shares
22,000 0.415
 
64,000 shares
64,000 0.410
 
53,500 shares
53,500 0.405
 
158,000 shares
158,000 0.400
Level two quotes - Ask
Ask Price Number of Shares
0.450 18,500
 
18,500 shares
0.455 60,500
 
60,500 shares
0.460 75,000
 
75,000 shares
0.465 32,000
 
32,000 shares
0.470 75,000
 
75,000 shares
0.475 42,500
 
42,500 shares
0.480 75,000
 
75,000 shares
0.485 22,000
 
22,000 shares
0.490 16,000
 
16,000 shares
0.500 133,000
 
133,000 shares

Bullboard Posts